A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes

Cardiovascular Diabetology

Volumn 16, Issue 1, 2017, Pages

  Jax, Thomas ^a,b   Stirban, Alin ^a   Terjung, Arne ^a   Esmaeili, Habib ^c   Berk, Andreas ^d   Thiemann, Sandra ^d   Chilton, Robert ^e   Eynatten, Maximilian ^d   Marx, Nikolaus ^f  

^a Profil Institut fur Stoffwechselforschung GmbH   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c Staburo GmbH   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Dipeptidyl peptidase 4 inhibitor; Endothelial function; Flow mediated vasodilation; Linagliptin; Macrovascular; Microvascular; Sulphonylurea; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LINAGLIPTIN; LOW DENSITY LIPOPROTEIN; METFORMIN; NITRIC OXIDE; PLACEBO; SULFONYLUREA; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, HUMAN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; BRACHIAL FLOW MEDIATED VASODILATION; CAPILLARY ENDOTHELIAL CELL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; HEART RATE; HUMAN; HYPEREMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; KIDNEY DISEASE; LASER DOPPLER FLOWMETRY; LIVER INJURY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PANCREATITIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN DEFECT; SMOKING; SYSTOLIC BLOOD PRESSURE; THENAR; VASODILATATION; AGED; BLOOD; BRACHIAL ARTERY; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIAGNOSTIC IMAGING; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MICROCIRCULATION; MICROVASCULATURE; MIDDLE AGED; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

AGED; BIOMARKERS; BRACHIAL ARTERY; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LINAGLIPTIN; MALE; METFORMIN; MICROCIRCULATION; MICROVESSELS; MIDDLE AGED; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME; VASODILATION;

EID: 85010190524     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0493-3     Document Type: Article

References (45)

1. Sena CM, Pereira AM, Seiça R. Endothelial dysfunction-a major mediator of diabetic vascular disease. Biochim Biophys Acta. 2013;1832(12):2216-31.
2. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(10):1285-95.
3. van Sloten TT, Henry RM, Dekker JM, Nijpels G, Unger T, Schram MT, et al. Endothelial dysfunction plays a key role in increasing cardiovascular risk in type 2 diabetes: the Hoorn study. Hypertension. 2014;64(6):1299-305.
4. de Jager J, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ, et al. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. Arterioscler Thromb Vasc Biol. 2006;26(5):1086-93.
5. Godinho R, Mega C, Teixeira-de-Lemos E, Carvalho E, Teixeira F, Fernandes R, et al. The place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: a "me too" or "the special one" antidiabetic class? J Diabetes Res. 2015;2015:806979.
6. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33(2):187-215.
7. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340-50.
8. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-42.
9. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-26.
10. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-35.
11. Noda Y, Miyoshi T, Oe H, Ohno Y, Nakamura K, Toh N, et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc Diabetol. 2013;12:8.
12. Noguchi K, Hirota M, Miyoshi T, Tani Y, Noda Y, Ito H, et al. Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals. Exp Ther Med. 2015;9(1):84-8.
13. Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T, et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc. 2013;2(1):e003277.
14. Kubota Y, Miyamoto M, Takagi G, Ikeda T, Kirinoki-Ichikawa S, Tanaka K, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci. 2012;27(11):1364-70.
15. Ott C, Raff U, Schmidt S, Kistner I, Friedrich S, Bramlage P, et al. Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol. 2014;13:19.
16. van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011;34(9):2072-7.
17. Nakamura K, Oe H, Kihara H, Shimada K, Fukuda S, Watanabe K, et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol. 2014;13:110.
18. Schmoelzer I, Wascher TC. Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance. Cardiovasc Diabetol. 2006;5:9.
19. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37(5):1344-50.
20. Vehkavaara S, Mäkimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Järvinen H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2000;20(2):545-50.
21. Rosenstock J, Marx N, Neubacher D, Seck T, Patel S, Woerle HJ, et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2015;14:57.
22. Suzuki K, Watanabe K, Suzuki T, Ouchi M, Futami-Suda S, Igari Y, et al. Sitagliptin improves vascular endothelial function in Japanese type 2 diabetes patients without cardiovascular disease. J Diabetes Mellitus. 2012;2(3):338-45.
23. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013;77(5):1337-44.
24. Hage C, Brismar K, Lundman P, Norhammar A, Rydén L, Mellbin L. The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: a report from the BEGAMI study. Diab Vasc Dis Res. 2014;11(4):290-3.
25. Maruhashi T, Higashi Y, Kihara Y, Yamada H, Sata M, Ueda S, et al. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study. Cardiovasc Diabetol. 2016;15(1):134.
26. Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, et al. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care. 2016;39(1):139-48.
27. Jax T. It may be premature to conclude a class effect of DPP-4 inhibitors on attenuating endothelial function measured by flow-mediated vasodilatation (electronic response to Ayaori M, et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc. 2013;2:e003277. doi: 10.1161/JAHA.112.003277).
28. Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res. 2013;10(4):289-301.
29. Cracowski JL, Minson CT, Salvat-Melis M, Halliwill JR. Methodological issues in the assessment of skin microvascular endothelial function in humans. Trends Pharmacol Sci. 2006;27(9):503-8.
30. Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A, et al. Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care. 1998;21(9):1529-33.
31. Negrean M, Stirban A, Stratmann B, Gawlowski T, Horstmann T, Götting C, et al. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2007;85(5):1236-43.
32. Stirban A, Nandrean S, Götting C, Tamler R, Pop A, Negrean M, et al. Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus. Am J Clin Nutr. 2010;91(3):808-13.
33. Kröller-Schön S, Knorr M, Hausding M, Oelze M, Schuff A, Schell R, et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res. 2012;96(1):140-9.
34. Salim HM, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Yagi S, et al. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice. Vascul Pharmacol. 2015;79:16-23.
35. Jyoti U, Kansal SK, Kumar P, Goyal S. Possible vasculoprotective role of linagliptin against sodium arsenite-induced vascular endothelial dysfunction. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(2):167-75.
36. Forst T, Michelson G, Diessel S, Jahnke J, Kapitza C. Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients. J Hypertens. 2016;34(2):345-50.
37. Ott C, Kistner I, Keller M, Friedrich S, Willam C, Bramlage P, Schmieder RE, et al. Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. Diabetologia. 2016;59(12):2579-87.
38. Baltzis D, Dushay JR, Loader J, Wu J, Greenman RL, Roustit M, et al. Effect of linagliptin on vascular function: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2016;101(11):4205-13.
39. Cooper ME, Perkovic V, McGill JB, Groop PH, Wanner C, Rosenstock J, et al. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis. 2015;66(3):441-9.
40. Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013;36(11):3460-8.
41. Berndt-Zipfel C, Michelson G, Dworak M, Mitry M, Löffler A, Pfützner A, et al. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study. Cardiovasc Diabetol. 2013;12:59.
42. Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, et al. GLP-1-based therapies have no microvascular effects in type 2 diabetes mellitus: an acute and 12-week randomized, double-blind, placebo-controlled trial. Arterioscler Thromb Vasc Biol. 2016;36(10):2125-32.
43. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
44. Matheeussen V, Baerts L, De Meyer G, De Keulenaer G, Van der Veken P, Augustyns K, et al. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem. 2011;392(3):189-98.
45. Jarnert C, Kalani M, Rydén L, Böhm F. Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study. Diab Vasc Dis Res. 2012;9(4):287-95.